Could a pill replace chemo for some breast cancers?
NCT ID NCT03283384
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether a combination of two drugs, ribociclib and letrozole, can replace standard chemotherapy for postmenopausal women with a common type of breast cancer (hormone receptor positive, HER2 negative). The study involves 100 participants who will receive either the drug combo or chemo before surgery. The goal is to see if the combo stops cancer cell growth as effectively as chemo, potentially offering a gentler treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ribociclib plus letrozole
What this could lead to
If successful, this could offer a less toxic, targeted alternative to chemotherapy for certain breast cancer patients before surgery.
What could go wrong
This is a small, early-phase trial (100 participants) and may not show that the drug combination works as well as chemotherapy. Side effects from ribociclib and letrozole are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
-
Amphia Ziekenhuis
Breda, Netherlands
-
Antonius Ziekenhuis
Sneek, Netherlands
-
Bravis Ziekenhuis
Roosendaal, Netherlands
-
Canisius-Wilhelmina Ziekenhuis
Nijmegen, Netherlands
-
Catharina Ziekenhuis
Eindhoven, Netherlands
-
Elisabeth Tweesteden Ziekenhuis
Tilburg, Netherlands
-
Gelre Ziekenhuizen
Apeldoorn, Netherlands
-
Groene Hart Ziekenhuis
Gouda, Netherlands
-
HAGA Ziekenhuis
The Hague, Netherlands
-
Haaglanden Medisch Centrum
The Hague, Netherlands
-
Isala
Zwolle, Netherlands
-
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
-
Laurentius Ziekenhuis
Roermond, Netherlands
-
Leiden University Medical Center
Leiden, Netherlands
-
Maxima Medisch Centrum
Eindhoven, Netherlands
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek
Amsterdam, Netherlands
-
Onze Lieve Vrouwe Gasthuis
Amsterdam, Netherlands
-
Spaarne Gasthuis
Haarlem, Netherlands
-
Stichting Deventer Ziekenhuisgroep
Deventer, Netherlands
-
Stichting Reinier Haga Groep (Reinier de Graaf Gasthuis)
Delft, Netherlands
-
Streekziekenhuis Koningin Beatrix
Winterswijk, Netherlands
-
Tergooi Ziekenhuizen
Hilversum, Netherlands
-
VieCuri Medisch Centrum
Venlo, Netherlands
-
Westfriesgasthuis
Hoorn, Netherlands
-
Ziekenhuis Amstelland
Amstelveen, Netherlands
-
Ziekenhuis Rivierenland
Tiel, Netherlands
-
Ziekenhuis St. Jansdal
Harderwijk, Netherlands
-
Ziekenhuisgroep Twente
Almelo, Netherlands